Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chitodex-budesonide-mupirocin gel for recalcitrant chronic rhinosinusitis
ACTRN12616000329460Phase 2Completed
- Sponsor
- The Queen Elizabeth Hospital
- Start
- Mar 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Chitodex, budesonide and mupirocin in chronic rhinosinusitis (CRS) (2 arms), sponsored by The Queen Elizabeth Hospital. Primary endpoints: Eradication of infection, Endoscopic sinus findings and 1 more. Started Mar 2016; status: completed.
02
Drugs
Chitodexbudesonidemupirocin
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ACTRN12616000329460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000329460.